The vision for personalized neuroscience is to translate insights about the human brain into real world clinical care, to improve the quality of individual lives.

Advances in human neuroscience and genomics give us new markers for understanding why one treatment works and another does not, but we have not yet bridged the translational divide between the evidence and how to apply this information in the real world.

In the PanLab, our current projects focus on depression and anxiety. We are also working on collaborative projects investigating psychosis and ADHD with anxiety as a cross disorder.

Our research embraces the study of heterogeneity and individual differences in the experience of mental disorder, and the associated disruptions to social and emotional function.

The Human Connectome Project aims to provide an unparalleled compilation of neural data, an interface to graphically navigate this data and the opportunity to achieve never before realized conclusions about the living human brain.

The Stanford Catalyst for Collaborative Solutions is a new initiative with a bold mission – to create an open space to explore uncommon interdisciplinary solutions to our world’s most pressing problems.

The Research on Anxiety and Depression: Anhedonia Treatment (RAD-AT) study is aimed at understanding treatment options for anhedonia, in particular Transcranial Magnetic Stimulation (TMS) and the medication pramipexole.

The International Study to Predict Optimized Treatment for Depression (iSPOT-D) study is aimed at identifying genetic, brain, and cognitive biomarkers that predict specific response to a range of antidepressants in patients diagnosed with major depressive disorder.

iSPOT-A Study

The International Study to Predict Optimized Treatment for Attention Deficit/Hyperactivity Disorder (iSPOT-A) study is aimed at identifying brain, genetic and cognitive markers that predict treatment response to short-acting methylphenidate in children and adolescents diagnosed with ADHD.